Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “lisdexamfetamine dimesylate” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 17
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 17 pipeline programs matching "lisdexamfetamine dimesylate" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

17 results for “lisdexamfetamine dimesylate” Back to intelligence hub

Search results

  1. Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    3 trials
  2. Lisdexamfetamine Dimesylate (LDX)

    Takeda

    ADHD

    phase 3 small molecule completed

    3 trials
  3. Lisdexamfetamine dimesylate

    Takeda

    Binge Eating Disorder

    phase 3 small molecule completed

    2 trials
  4. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    2 trials
  5. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Binge Eating Disorder

    phase 3 small molecule completed

    2 trials
  6. SPD489 (Lisdexamfetamine dimesylate) + Antidepressant

    Takeda

    Major Depressive Disorder

    phase 3 small molecule terminated

    1 trial
  7. Vyvanse (lisdexamfetamine dimesylate)

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial
  8. SPD489 (lisdexamfetamine dimesylate)

    Takeda

    Schizophrenia and Predominant Negative Symptoms

    phase 2 small molecule completed

    1 trial
  9. lisdexamfetamine dimesylate (SPD489)

    Takeda

    Binge Eating Disorder

    phase 2 small molecule completed

    1 trial
  10. Lisdexamfetamine Dimesylate

    Takeda

    Healthy

    phase 1 small molecule terminated

    1 trial
  11. Lisdexamfetamine Dimesylate

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials
  12. Lisdexamfetamine Dimesylate (LDX)

    Takeda

    Attention-Deficit Hyperactivity Disorder

    phase 1 small molecule completed

    1 trial
  13. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Schizophrenia

    phase 1 small molecule completed

    1 trial
  14. Lisdexamfetamine dimesylate

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    approved small molecule completed

    1 trial
  15. Lisdexamfetamine dimesylate

    Takeda

    Attention-deficit/Hyperactivity Disorder

    approved small molecule completed

    3 trials
  16. SPD489 (Lisdexamfetamine dimesylate)

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    approved small molecule completed

    1 trial
  17. Vyvanse (lisdexamfetamine dimesylate)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    approved small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.